ARTICLE | Finance
PTC's waiting game
PTC raises $60M from group led by mezzanine investors but isn’t rushing to exit
March 18, 2013 7:00 AM UTC
Mezzanine investors piled into PTC Therapeutics Inc. and took two board seats in conjunction with last week's $60 million private round. But one investor who requested anonymity told BioCentury that PTC's board is in no rush to take the genetic disorder company public.
The financing was led by new investor Brookside Capital, the public equity affiliate of Bain Capital. Additional new investors included Adage Capital; Jennison Associates; Longwood Fund; and institutional investors...